EN
New 8-Heterocyclic Xanthine Derivatives as Antiproliferative Agents: Synthesis and Biological Evaluation
Abstract
This research focuses on the synthesis, characterization, and evaluation of the anti-cancer activity of novel 8-aryl substituted 1,3-diethylxanthine derivatives. The anti-proliferative activities of all the compounds were assessed using an MTT assay on four human cancer cell lines: breast cancer MCF7, human lung cancer A549, human brain cancers LN229, and U87. One of the derivatives of 1,3-diethylxanthine with a thiazole structure displayed strong anti-proliferative activity. 1,3-Diethyl-8-(thiazol-4-yl)-3,7-dihydro-1H-purine-2,6-dione (5) exhibited the strongest activity against A549, MCF7, LN229, and U87 cell lines, with IC50 values of 16.70, 78.06, 22.07, and 25.07 μM, respectively. Furthermore, the scratch assay was conducted to evaluate the effect of compound 5 on the inhibition of cell migration in A549 cells. The consistent results demonstrate that compound 5 exhibits potent anti-cancer activity, which could be further investigated to enhance its biological potential.
Keywords
References
- 1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians. 2023 Jan;73(1):17–48. Available from:
- 2. Ioele G, Chieffallo M, Occhiuzzi MA, De Luca M, Garofalo A, Ragno G, et al. Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. Molecules. 2022 Aug;27(17):5436. Available from:
- 3. Pal R, Teli G, Matada GSP, Dhiwar PS. Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibitors. Journal of Molecular Structure. 2023 Nov;1291:136021. Available from:
- 4. Taruneshwar Jha K, Shome A, Chahat, Chawla PA. Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship. Bioorganic Chemistry. 2023 Sep;138:106680. Available from:
5. Sharma PC, Bansal KK, Sharma A, Sharma D, Deep A. Thiazole-containing compounds as therapeutic targets for cancer therapy. European Journal of Medicinal Chemistry. 2020 Feb;188:112016. Available from: 6. Roy A, Kumar Bahe A, Chanderiya A, Dangi H, Mishra P, Mishra AK, et al. Synthesis of Nitrogen-and Oxygen-Containing Heterocyclic Compounds Using Nanocatalyst: A Review. Journal of the Turkish Chemical Society Section A: Chemistry. 2021 Aug;8(3):851-862. Available from: - 7. Persson C. Development of safer xanthine drugs for treatment of obstructive airways disease. Journal of Allergy and Clinical Immunology. 1986 Oct;78(4):817–24. Available from:
- 8. Persson CGA, Kjellin G. Enprofylline, a Principally New Antiasthmatic Xanthine. Acta Pharmacol Toxicol (Copenh). 1981 Oct;49:313-316. Available from:
9. Müller CE, Jacobson KA. Xanthines as Adenosine Receptor Antagonists. Handbook of Experimental Pharmacology. 2011 200:151-99. Available from: - 10. Hayallah AM, Elgaher WA, Salem OI, Abdel Alim AAM. Design and synthesis of some new theophylline derivatives with bronchodilator and antibacterial activities. Archives of Pharmacal Research. 2011 Jan;34(1):3–21. Available from:
11. Singh N, Kumar Shreshtha A, Thakur MS, Patra S. Xanthine scaffold: scope and potential in drug development. Heliyon. 2018 Sep;4:829. Available from: - 12. Bhat VB, Madyastha KM. Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochemical and Biophysical Research Communications. 2001 Nov;288(5):1212–7. Available from:
Details
Primary Language
English
Subjects
Organic Chemical Synthesis, Biologically Active Molecules
Journal Section
Research Article
Authors
Publication Date
May 15, 2024
Submission Date
August 9, 2023
Acceptance Date
November 20, 2023
Published in Issue
Year 2024 Volume: 11 Number: 2
APA
Sucu, B. O. (2024). New 8-Heterocyclic Xanthine Derivatives as Antiproliferative Agents: Synthesis and Biological Evaluation. Journal of the Turkish Chemical Society Section A: Chemistry, 11(2), 533-540. https://doi.org/10.18596/jotcsa.1340105
AMA
1.Sucu BO. New 8-Heterocyclic Xanthine Derivatives as Antiproliferative Agents: Synthesis and Biological Evaluation. JOTCSA. 2024;11(2):533-540. doi:10.18596/jotcsa.1340105
Chicago
Sucu, Bilgesu Onur. 2024. “New 8-Heterocyclic Xanthine Derivatives As Antiproliferative Agents: Synthesis and Biological Evaluation”. Journal of the Turkish Chemical Society Section A: Chemistry 11 (2): 533-40. https://doi.org/10.18596/jotcsa.1340105.
EndNote
Sucu BO (May 1, 2024) New 8-Heterocyclic Xanthine Derivatives as Antiproliferative Agents: Synthesis and Biological Evaluation. Journal of the Turkish Chemical Society Section A: Chemistry 11 2 533–540.
IEEE
[1]B. O. Sucu, “New 8-Heterocyclic Xanthine Derivatives as Antiproliferative Agents: Synthesis and Biological Evaluation”, JOTCSA, vol. 11, no. 2, pp. 533–540, May 2024, doi: 10.18596/jotcsa.1340105.
ISNAD
Sucu, Bilgesu Onur. “New 8-Heterocyclic Xanthine Derivatives As Antiproliferative Agents: Synthesis and Biological Evaluation”. Journal of the Turkish Chemical Society Section A: Chemistry 11/2 (May 1, 2024): 533-540. https://doi.org/10.18596/jotcsa.1340105.
JAMA
1.Sucu BO. New 8-Heterocyclic Xanthine Derivatives as Antiproliferative Agents: Synthesis and Biological Evaluation. JOTCSA. 2024;11:533–540.
MLA
Sucu, Bilgesu Onur. “New 8-Heterocyclic Xanthine Derivatives As Antiproliferative Agents: Synthesis and Biological Evaluation”. Journal of the Turkish Chemical Society Section A: Chemistry, vol. 11, no. 2, May 2024, pp. 533-40, doi:10.18596/jotcsa.1340105.
Vancouver
1.Bilgesu Onur Sucu. New 8-Heterocyclic Xanthine Derivatives as Antiproliferative Agents: Synthesis and Biological Evaluation. JOTCSA. 2024 May 1;11(2):533-40. doi:10.18596/jotcsa.1340105
